MTX

Novel Approach Uses a Smartphone App to Remotely Quantify RA Patients’ Temporally Related Unwanted Symptoms Related to Methotrexate Administration

Retrieved on: 
Lundi, décembre 20, 2021
Physical Therapy, Technology, Men, Science, Family, Consumer, Biotechnology, Health, Other Science, Research, Software, Other Health, Other Consumer, Women, Pharmaceutical, Data Management, Seniors, MTX, Digital technology, Time, Patient, Psoriatic arthritis, Rheumatism, National, Arthritis, Fatigue, PROMIS, Rheumatoid arthritis, Development, Â, RA, Doctor of Philosophy, Validation, DMARD, Nausea, Disease-modifying antirheumatic drug, Birmingham, Injury, Amgen, Patient-Reported Outcomes Measurement Information System, Research, Disease, Social media, MID, Diagnosis, Education, Methotrexate, PRO, Use, Conditional sentence, A Call for Unity, University, MPH, Caregiver, Immunology, Human voice, Risk, Ageing, Pharmaceutical industry, Medical device, Rheumatology, Adult, MD, Medicine

It also demonstrates that the use of digital technology to assess medication-related symptoms is both feasible and acceptable to patients.

Key Points: 
  • It also demonstrates that the use of digital technology to assess medication-related symptoms is both feasible and acceptable to patients.
  • The study, Patient-Reported Nausea and Fatigue Related to Methotrexate: A Prospective, Self-Controlled Study in the ArthritisPower Registry , was published in Rheumatology and Therapy (28 Nov. 2021).
  • MTX has a reasonable effectiveness and safety profile that has been well documented in prior studies but is known to induce unwanted symptoms among some patients who take it.
  • CreakyJoints publishes the popular Raising the Voice of Patients series, which offers downloadable patient-centered educational and navigational tools for managing chronic illness.

Minerals Technologies Announces Two New Satellite Contracts in Asia

Retrieved on: 
Jeudi, décembre 16, 2021
PCC, Calcium carbonate, NYSE, Paper, MTI, SPB, MTX, Steel, Contract, GLOBE, GCC, Technology

NEW YORK, Dec. 16, 2021 (GLOBE NEWSWIRE) -- Minerals Technologies Inc. (NYSE: MTX) (“MTI” or “the Company”) announced today that it has entered into two separate long-term agreements.

Key Points: 
  • The first agreement is to deploy ground calcium carbonate (GCC) technology with Asia Symbol, a premier pulp, paper, and packaging company in China.
  • This represents MTIs first GCC satellite offering specifically tailored for packaging customers.
  • The agreement with Asia Symbol represents a fundamental step in our ability to drive new growth opportunities in the white paperboard market.
  • In addition, our new satellite with SPB will be our ninth in India, continuing our geographic growth in the region.

SIENA COLLEGE RECEIVES $35 MILLION DONATION - LARGEST SINGLE GIFT IN ITS HISTORY

Retrieved on: 
Mardi, décembre 14, 2021
Consensus, Cloud, Organization, Siena Saints football, 1993 NCAA Division III football season, Hope, National Center for Education Statistics, NCAA, Education, Siena College, City, Nobel Prize, U.S. Department of Education, Office of Inspector General, Salesforce, Board, Trustee, Growth, Google Cloud, Nobel Foundation, Foundation (nonprofit), Science, COVID-19, Artificial intelligence, Family, National Center on Education and the Economy, AI, NYS, Happiness, Catholic (term), CEO, U.S. Department of Labor, Office of Inspector General, AWS, Culture, Board of directors, Amazon Web Services, Laboratory, MTX, U.S. Department of Defense Strategy for Operating in Cyberspace, College, Ernst, Student, Health, Management, Pharmaceutical industry, Medicine, Nobel

The announcement of their gift, which came as a surprise to the Siena community, was shared on December 14 during a special campus event.

Key Points: 
  • The announcement of their gift, which came as a surprise to the Siena community, was shared on December 14 during a special campus event.
  • We are incredibly grateful for their generosity, which will transform the way Siena prepares our students for their own careers."
  • Siena College is a private, co-educational liberal arts college in the Franciscan and Catholic tradition.
  • Founded in 1937, Siena offers 40 majors, 80-plus minors and certificates, and prestigious joint-degree programs in liberal arts, science and business.

SinoMab Announces the Completion of Enrollment in Phase III Clinical Trial in China for its Flagship Product, SM03

Retrieved on: 
Mardi, novembre 30, 2021
Patient, SM03, CD22, Safety, B-cell lymphoma, Asthma, Company, Rheumatoid arthritis, Clinical trial, Mab, RA, Therapy, MTX, Research, Thirteenth, III, Twelfth, The Company, Methotrexate, Anti-CD22 immunotoxin, Lupus, Pharmaceutical industry

The patients currently in screening will be randomized by end of December 2021, given eligibility criteria are met.

Key Points: 
  • The patients currently in screening will be randomized by end of December 2021, given eligibility criteria are met.
  • SM03 (Suciraslimab), a potential global first-in-target anti-CD22 monoclonal antibody for the treatment of RA and potentially for the treatment of other immunological diseases, is currently in Phase III clinical trials in China.
  • The Phase III clinical trial is a multi-center, randomized, double-blind, placebo-controlled, parallel group study to confirm the clinical efficacy and long-term safety in active RA patients receiving methotrexate (MTX).
  • The efficacy and safety of Suciraslimab was previously evaluated in a phase II clinical study in moderate-to-severely active RA patients.

SERB receives positive CHMP opinion for Voraxaze® (glucarpidase) as Rescue Therapy for High Dose Methotrexate Toxicity

Retrieved on: 
Mardi, novembre 30, 2021
Royal commission, Patient, Organic acid, COMP, News, European Medicines Agency, Leukemia, Lymphoma, European Union, Plasma, Committee on Herbal Medicinal Products, Recurrence, Cancer, Committee, BTG, Community, Ageing, Kidney, Ministry, MTX, CHMP, Thymidine, List of health departments and ministries, Risk, EMA, Marketing, Union, FDA, European Commission, Ministry of Health, Labour and Welfare, Committee for Medicinal Products for Human Use, Osteosarcoma, Multimedia, SERB, Congress, Methotrexate, Toxicity, Degenerative disease, Liver, Pharmaceutical industry

"Prolonged exposure to high concentrations of methotrexate can cause severe and potentially life-threatening toxicity," said Antoine Bernasconi, SERB Chief Commercial Officer.

Key Points: 
  • "Prolonged exposure to high concentrations of methotrexate can cause severe and potentially life-threatening toxicity," said Antoine Bernasconi, SERB Chief Commercial Officer.
  • "This positive CHMP opinion for Voraxaze is an important step toward offering a reliable and specific rescue therapy for cancer patients in Europe who experience toxic methotrexate concentrations."
  • The efficacy of Voraxaze has been evaluated in four open-label, multi-centre studies in patients with delayed methotrexate elimination.
  • In patients with methotrexate concentrations measured by chromatographic methods, a median reduction of > 97% in methotrexate concentration occurred within 15 minutes following Voraxaze administration.

SERB receives positive CHMP opinion for Voraxaze® (glucarpidase) as Rescue Therapy for High Dose Methotrexate Toxicity

Retrieved on: 
Mardi, novembre 30, 2021
Royal commission, Patient, Organic acid, COMP, News, European Medicines Agency, Leukemia, Lymphoma, European Union, Plasma, European Directive on Traditional Herbal Medicinal Products, Recurrence, Cancer, Committee, BTG, Community, Ageing, Kidney, Ministry, MTX, CHMP, Thymidine, List of health departments and ministries, Risk, EMA, Marketing, Union, FDA, European Commission, Ministry of Health, Labour and Welfare, Committee for Medicinal Products for Human Use, Osteosarcoma, Congress, SERB, Methotrexate, Toxicity, Degenerative disease, Liver, Pharmaceutical industry

LONDON, Nov. 30, 2021 /PRNewswire/ -- SERB and BTG Specialty Pharmaceuticals today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending a marketing authorisation for Voraxaze® (glucarpidase) to reduce toxic plasma methotrexate concentration in adults and children (aged 28 days and older) with delayed methotrexate elimination or at risk of methotrexate toxicity.

Key Points: 
  • "Prolonged exposure to high concentrations of methotrexate can cause severe and potentially life-threatening toxicity," said Antoine Bernasconi, SERB Chief Commercial Officer.
  • "This positive CHMP opinion for Voraxaze is an important step toward offering a reliable and specific rescue therapy for cancer patients in Europe who experience toxic methotrexate concentrations."
  • The efficacy of Voraxaze has been evaluated in four open-label, multi-centre studies in patients with delayed methotrexate elimination.
  • In patients with methotrexate concentrations measured by chromatographic methods, a median reduction of > 97% in methotrexate concentration occurred within 15 minutes following Voraxaze administration.

MTX Group Co-Founders Named National Award Winners for EY's Entrepreneurs of the Year

Retrieved on: 
Jeudi, novembre 18, 2021
Cloud, LLP, Happiness, Technology, AI, EY, Health, Culture, Google Cloud, Economics, Year, Education, Solution, National Film Awards, COVID-19, Salesforce, MTX, Platform, Artificial intelligence, Entrepreneurship, Ernst & Young, Organization, Amazon Web Services, Ernst & Young Entrepreneur of the Year Award, Nipa, Government, Multimedia, Lifting, Disease, AWS, National, Management

The 2021 National award winners were announced during the National awards gala at the Strategic Growth Forum this past weekend.

Key Points: 
  • The 2021 National award winners were announced during the National awards gala at the Strategic Growth Forum this past weekend.
  • Entrepreneur Of The Year recognizes the most ambitious leaders who are building and sustaining successful, dynamic businesses around the world.
  • Entrepreneur Of The Year Award winners comprise a global network of like-minded visionaries, each on a transformational journey to create, innovate, grow, learn and build a better world.
  • "Nipa and I are truly honored to be selected as National award winners for EY's Entrepreneur of the Year," said CEO Das Nobel.

Jyseleca®▼(filgotinib) approved in the European Union for the treatment of ulcerative colitis

Retrieved on: 
Lundi, novembre 15, 2021
Population, Federalisation of the European Union, Ministry of Health, Labour and Welfare, Principal, European Commission, Review, Colon, Dysentery, MTX, European, Disease-modifying antirheumatic drug, MHRA, Rectum, Teaching hospital, UC, Commission, PMDA, CET, Methotrexate, Tablet, Patient, Adult, Quality of life, Health care, Eisai, Ulcerative colitis, Inflammatory bowel disease, CEO, Disease, Medicines and Healthcare products Regulatory Agency, Inflammation, Union, Goal, Product, Steroid, Fatigue, Contraindication, Galapagos NV, Gilead Sciences, Euronext, IBD, Gilead, European Union, JAK1, RA, Interview, HTTPS, Incontinence, Physician, Fibrosis, Royal commission, Abdominal pain, Pharmaceutical industry

We are very pleased that the European Commission has approved Jyseleca as a treatment for people with UC.

Key Points: 
  • We are very pleased that the European Commission has approved Jyseleca as a treatment for people with UC.
  • This decision further supports the efficacy and safety profile of Jyseleca, which was studied in over 1,250 UC patients.
  • Our focus now is on making this treatment available as rapidly as possible to physicians and UC patients across the European Union, said Onno van de Stolpe, CEO of Galapagos.
  • Having new approved treatment choices is therefore very important, and at EFCCA we are pleased to see new options being made available.

Exagen Inc. Reports Third Quarter 2021 Results

Retrieved on: 
Mercredi, novembre 10, 2021
Lupus, Science, Private Securities Litigation Reform Act, MTX, Medicare, SAN, Investor relations, Movement, Security (finance), Technology, Prognosis, Investment, Rheumatoid arthritis, Growth, Goal, COVID-19, Research, 2021 Essex County Council election, Annual report, Partnership, Rheumatology, American College of Rheumatology, U.S. Securities and Exchange Commission, GLOBE, Therapy, Cell-bound complement activation products, SEC, Webcast, Review, Interest, CTD, Patient, American College, Lithium, Video game, Pharmaceutical industry

SAN DIEGO, Nov. 10, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN),a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended September30, 2021.

Key Points: 
  • SAN DIEGO, Nov. 10, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN),a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended September30, 2021.
  • Generated total revenue of $12.3 million for the third quarter of 2021, a 14% increase over the third quarter of 2020.
  • Delivered 31,742 AVISE CTD tests, including AVISE Lupus, in the third quarter of 2021, a 21% increase over the third quarter of 2020.
  • A conference call to review third quarter 2021 financial results and to provide a business update is scheduled for today November 10, 2021 at 4:30 PM ET (1:30 PM PT).

MTX Group and Ascent Soccer Announce Partnership To Develop Leadership Academy

Retrieved on: 
Mercredi, novembre 3, 2021
Cloud, Quality of life, Technology, Empowerment, U13, Happiness, Industry, Character, Association football, Organization, Partnership, MTX, Google Cloud, Democratic republic, Leadership, Athlete, Congo, Economics, Multimedia, Male, Artificial intelligence, Health, Association, Female, Football, Amazon Web Services, AWS, Education, Salesforce, AI, Sport, Marketing, Tourism, Toy

FRISCO, Texas, Nov. 3, 2021 /PRNewswire/ -- MTX Group Inc (MTX) , a global technology consulting firm, officially announced a new partnership with US-based nonprofit Ascent Soccer .

Key Points: 
  • FRISCO, Texas, Nov. 3, 2021 /PRNewswire/ -- MTX Group Inc (MTX) , a global technology consulting firm, officially announced a new partnership with US-based nonprofit Ascent Soccer .
  • MTX and Ascent Soccer will develop a sustainable leadership academy to expand transformational opportunities in East Africa through soccer.
  • "We're thrilled to welcome an industry leader like MTX to the Ascent Soccer family," said Ascent Soccer Co-founder Adrian Bradbury.
  • Ascent Soccer empowers talent and promise in Malawi and Uganda as the greenest soccer academy on the continent.